23andMe Investor Day Presentation Deck
Agenda
Introduction -- Anne Wojcicki, CEO and Co-Founder
23andMe Therapeutics
Therapeutics program overview - Kenneth Hillan, Head of Therapeutics
Target discovery vision - Joe Arron, Chief Scientific Officer, Therapeutics
Genetics-based target discovery - Adam Auton, VP of Human Genetics
CD200R1 immuno-oncology program - Jennifer Low, Head of Therapeutics Development and Adrian Jubb, Sr. Clin. Dev. Fellow, Therapeutics
CD96 immuno-oncology program - Jennifer Low, Head of Therapeutics Development
Using genetics to inform clinical development - Jennifer Low, Head of Therapeutics Development
Therapeutics program concluding remarks - Kenneth Hillan, Head of Therapeutics
23andMe Consumer
Genetics-based primary care - Paul Johnson, VP, General Manager, Consumer
The power of polygenic risk scores (PRS) for personalized health Geoff Benton, Director, Product R&D
Delivering a genetic-based primary care service - Davis Liu, Chief Clinical Officer
Concluding Remarks - Anne Wojcicki, CEO and Co-Founder
Q&A
Copyright © 2022 23andMe, Inc.
23andMe
3View entire presentation